AU2004205659B2 - MNTF peptides and compositions and methods of use - Google Patents

MNTF peptides and compositions and methods of use Download PDF

Info

Publication number
AU2004205659B2
AU2004205659B2 AU2004205659A AU2004205659A AU2004205659B2 AU 2004205659 B2 AU2004205659 B2 AU 2004205659B2 AU 2004205659 A AU2004205659 A AU 2004205659A AU 2004205659 A AU2004205659 A AU 2004205659A AU 2004205659 B2 AU2004205659 B2 AU 2004205659B2
Authority
AU
Australia
Prior art keywords
seq
peptide
effective amount
peptide analogue
mntf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004205659A
Other languages
English (en)
Other versions
AU2004205659A1 (en
Inventor
Raymond Ming Wah Chau
Pui-Yuk Dorothy Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genervon Biopharmaceuticals LLC
Original Assignee
Genervon Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genervon Biopharmaceuticals LLC filed Critical Genervon Biopharmaceuticals LLC
Publication of AU2004205659A1 publication Critical patent/AU2004205659A1/en
Application granted granted Critical
Publication of AU2004205659B2 publication Critical patent/AU2004205659B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
AU2004205659A 2003-01-21 2004-01-21 MNTF peptides and compositions and methods of use Ceased AU2004205659B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44177203P 2003-01-21 2003-01-21
US60/441,772 2003-01-21
PCT/US2004/001468 WO2004065410A2 (en) 2003-01-21 2004-01-21 Mntf peptides and compositions and methods of use

Publications (2)

Publication Number Publication Date
AU2004205659A1 AU2004205659A1 (en) 2004-08-05
AU2004205659B2 true AU2004205659B2 (en) 2009-03-26

Family

ID=32771972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004205659A Ceased AU2004205659B2 (en) 2003-01-21 2004-01-21 MNTF peptides and compositions and methods of use

Country Status (9)

Country Link
US (2) US7183373B2 (enExample)
EP (1) EP1587526B1 (enExample)
JP (3) JP2006516287A (enExample)
AT (1) ATE530191T1 (enExample)
AU (1) AU2004205659B2 (enExample)
CA (1) CA2506855C (enExample)
DK (1) DK1587526T3 (enExample)
ES (1) ES2375797T3 (enExample)
WO (1) WO2004065410A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841531B2 (en) 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors
WO2004065410A2 (en) * 2003-01-21 2004-08-05 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use
AU2006315668B2 (en) * 2005-11-10 2013-06-20 Genervon Biopharmaceuticals Llc MNTF differentiation and growth of stem cells
US8340193B2 (en) * 2006-08-04 2012-12-25 Microsoft Corporation Wyner-Ziv and wavelet video coding
US8673852B2 (en) * 2006-11-10 2014-03-18 Genervon Biopharmaceuticals, LLC Methods of treating neuronal disorders using MNTF peptides and analogs thereof
EP2000134A1 (en) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Use of a substance for the improvement of pns lesions
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
CN101952306B (zh) * 2008-02-21 2014-09-10 皮护神经科学协会 Mntf肽的化妆和皮肤病制剂
US8846615B2 (en) * 2008-02-21 2014-09-30 Genervon Biopharmaceuticals, LLC MNTF peptides
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
MX428431B (es) 2021-05-18 2025-11-13 Ltt Bio Pharma Co Ltd Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086831A1 (en) * 1996-09-27 2002-07-04 Chau Raymond Ming Wah Methods and use of motoneuronotrophic factors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309877B1 (en) * 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
WO2004065410A2 (en) * 2003-01-21 2004-08-05 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086831A1 (en) * 1996-09-27 2002-07-04 Chau Raymond Ming Wah Methods and use of motoneuronotrophic factors

Also Published As

Publication number Publication date
US7183373B2 (en) 2007-02-27
US20080125373A1 (en) 2008-05-29
US7795215B2 (en) 2010-09-14
ES2375797T3 (es) 2012-03-06
CA2506855C (en) 2013-08-27
WO2004065410A2 (en) 2004-08-05
JP2012046538A (ja) 2012-03-08
JP4913895B2 (ja) 2012-04-11
WO2004065410A3 (en) 2004-12-16
ATE530191T1 (de) 2011-11-15
DK1587526T3 (da) 2012-02-06
EP1587526B1 (en) 2011-10-26
EP1587526A2 (en) 2005-10-26
CA2506855A1 (en) 2004-08-05
JP2011042659A (ja) 2011-03-03
EP1587526A4 (en) 2008-01-02
AU2004205659A1 (en) 2004-08-05
JP2006516287A (ja) 2006-06-29
US20060052299A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
US7795215B2 (en) MNTF peptides and compositions and methods of use
JP2009102392A (ja) プロテインキナーゼｃのペプチドインヒビター
JP2007209349A (ja) 新規な神経栄養因子
US8765673B2 (en) Methods for promoting wound healing and/or reducing scar formation
WO1998022499A9 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
JP4402455B2 (ja) 細胞の分化、増殖、再生、可塑性及び生存に影響を及ぼすことができる化合物
AU2009217266B2 (en) MNTF peptide compositions and methods of use
US6329500B1 (en) Transforming growth factor-β binding site
AU2007200957B2 (en) Methods for promoting wound healing and/or reducing scar formation
CA2221391A1 (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof
AU2004238332A2 (en) Novel fibroblast growth factors and methods of use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTOR NAME FROM KO, TIU-YAK DOROTHY TO KO, PUI-YUK DOROTHY.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired